This prospective cohort study aims to assess the impact of gender-affirming hormone therapy (GAHT) on transgender individuals' physical, psychological, social, and quality of life aspects. Based on gender minority stress theory, the research recruits 150 individuals each of those starting GAHT and those not yet undergoing it. Data collection involves questionnaires and physiological measurements. Statistical analyses will explore correlations and group differences. Findings can guide transgender individuals considering hormone therapy and enhance care guidelines to improve their overall well-being.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Transgender Congruence Scale
Timeframe: 1 year
Gender Affirming Hormone Treatment Physical Symptoms Assessment Scale
Timeframe: 1 year
Sexual Risk Survey (SRS) Items
Timeframe: 1 year
Short Sexual Well Being Scale
Timeframe: 1 year
Transgender individual Quality of Life
Timeframe: 1 year
Beck Depression Inventory-II
Timeframe: 1 year
Multidimensional Perceived Social Support Scale
Timeframe: 1 year